You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,493,080


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,493,080
Title:Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
Inventor(s): Schultz; Peter (La Jolla, CA), Lairson; Luke (San Diego, CA), Deshmukh; Vishal (La Jolla, CA), Lyssiotis; Costas (Boston, MA)
Assignee: The Scripps Research Institute (La Jolla, CA) Novartis AG (Basel, CH)
Application Number:15/418,572
Patent Claims:1. A method of stimulating increased myelination of nerves in a human subject having a demyelinating disease, the method comprising: administering to the subject a muscarinic receptor antagonist as a neurotransmitter receptor modulating agent in an amount sufficient to stimulate oligodendrocyte precursor cell differentiation in the subject, thereby stimulating increased myelination of nerves in the subject, wherein the muscarinic receptor antagonist is selected from benztropine, carbetapentane, clemastine, and salts thereof.

2. A method of stimulating increased myelination of nerves in a human subject having a demyelinating disease, the method comprising: administering to the subject a dopamine receptor antagonist as a neurotransmitter receptor modulating agent in an amount sufficient to stimulate oligodendrocyte precursor cell differentiation in the subject, thereby stimulating increased myelination of nerves in the subject, wherein the dopamine receptor antagonist is selected from benztropine, GBR12935, trifluoperazine, and salts thereof.

3. A method of stimulating increased myelination of nerves in a human subject having a demyelinating disease, the method comprising: administering to the subject a neurotransmitter receptor modulating agent selected from the group consisting of a histamine receptor antagonist, a beta adrenergic receptor antagonist, and an opioid receptor modulator in an amount sufficient to stimulate oligodendrocyte precursor cell differentiation in the subject, thereby stimulating increased myelination of nerves in the subject, wherein the histamine receptor antagonist is clemastine or a salt thereof, or wherein the beta adrenergic receptor antagonist is salbutamol or a salt thereof, or wherein the opioid receptor modulator is carbetapentane or a salt thereof.

4. The method of claim 1, wherein the demyelinating disease is multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukodystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot-Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or HTLV-associated myelopathy.

5. The method of claim 4, wherein the demyelinating disease is multiple sclerosis.

6. The method of claim 1, wherein the subject has been administered an immunomodulatory agent.

7. The method of claim 6, wherein the immunomodulatory agent is fingolimod (FTY720), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, or natalizumab.

8. The method of claim 2, wherein the demyelinating disease is multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukodystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot-Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or HTLV-associated myelopathy.

9. The method of claim 8, wherein the demyelinating disease is multiple sclerosis.

10. The method of claim 2, wherein the subject has been administered an immunomodulatory agent.

11. The method of claim 10, wherein the immunomodulatory agent is fingolimod (FTY720), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, or natalizumab.

12. The method of claim 3, wherein the demyelinating disease is multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukodystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot-Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or HTLV-associated myelopathy.

13. The method of claim 12, wherein the demyelinating disease is multiple sclerosis.

14. The method of claim 3, wherein the subject has been administered an immunomodulatory agent.

15. The method of claim 14, wherein the immunomodulatory agent is fingolimod (FTY720), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, or natalizumab.

16. The method of claim 1, wherein the muscarinic receptor antagonist is selected clemastine or a salt thereof.

Details for Patent 10,493,080

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 ⤷  Try a Trial 2031-02-18
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 05/17/1996 ⤷  Try a Trial 2031-02-18
Biogen Inc. AVONEX interferon beta-1a Injection 103628 05/28/2003 ⤷  Try a Trial 2031-02-18
Biogen Inc. AVONEX interferon beta-1a Injection 103628 02/27/2012 ⤷  Try a Trial 2031-02-18
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 03/07/2002 ⤷  Try a Trial 2031-02-18
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 12/17/2004 ⤷  Try a Trial 2031-02-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.